Clinical research of adefovir dipivoxil tablets combined with Fufangbiejiaruangan tablets on treating hepatic fibrosis following chronic hepatitis B

Objective:Clinical research of adefovir dipivoxil tablets combined with Fufangbiejiaruangan tablets on treating hepatic fibrosisn following chronic hepatitis B.Methods:Eighty-two cases of hepatic fibrosis following chronic hepatitis B were divided randomly into treatment group and contrast group.The treatment group was treated by adefovir dipivoxil tablets combined with Fufangbiejiaruangan tablets orally.The contrast group was treated by adefovir dipivoxil tablets.After 12 months of therapy,indices including liver histology,liver function,liver fibrosis,B ultrasonic,quantification of HBV DNA were tested and compared.Results:After treatment,the total effective rate of the treatment group was 90.4%.The total effective rate of the contrast group was 77.5%.The clinical effect of treatment group was significantly better than that of contrast group.After treatment,the AST,TBil,HA levels of the treatment group were improved obviously compared with those before treatment.The clinical effect of treatment group was significantly better than that of contrast group.The diameters of hepatic portal veins and splenic veins,the thickness of spleen were significantly less than those of contrast group.After treatment,the differences in quantitative detection of serum HBV DNA between the two groups did not have any statistic significance.Conclusion:The treatment of adefovir dipivoxil tablets combined with Fufangbiejiaruangan tablets has greatly improved patients condition as well as prognosis by antivirus and anti-fibrosis.